Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804807 | 1.00 | MEN1 (0.52) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6803601 | 0.83 | KMT2A (0.53) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL6803602 | 0.83 | KMT2A (0.53) | MEN1KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL6799332 | 0.82 | RAB9A (0.56) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6799335 | 0.82 | RAB9A (0.56) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6804254 | 0.82 | RAB9A (0.56) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6433955 | 0.80 | TYR (0.45) | TYRSMYD3DRD2HTR2ADRD3 | |
| SCHEMBL2230140 | 0.79 | NPC1 (0.79) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL124395 | 0.79 | NPC1 (0.79) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3658943 | 0.78 | NPC1 (0.60) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885NPC1 2629/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885NPC1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.